An Introduction to Lymphoma
Lymphoma is one of the ten most common malignancies worldwide. While some lymphomas are curable, the treatment of relapsed and refractory disease remains a substantial challenge. Recent advances have led to the development of a number of new treatment strategies, including novel antibodies targeting surface antigens, small molecular inhibitors targeting oncogenic signalling pathways and tumour suppressors, and immune checkpoint inhibitors. Chimeric antigen receptor (CAR) T-cells offer the potential for personalised therapy. The emergence of so many new therapeutic options have raised challenges in terms of optimal sequencing and combined approaches, and have highlighted the need for biomarkers to predict therapeutic response.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Managing the practicalities of CAR T-cell therapies in patients with R/R MCL: Current considerations and future strategies
Watch haemato-oncology experts discuss updates in managing R/R mantle cell lymphoma with CAR T-cell therapy.
- Review current treatment strategies for relapsed/refractory mantle cell lymphoma, including the role of CAR T-cell therapy
- Formulate practical strategies for the management of CAR T-cell-associated toxicities and treatment failure in patients with relapsed/refractory mantle cell lymphoma
- Discuss future considerations for optimizing CAR T-cell therapy in relapsed/refractory mantle cell lymphoma
New horizons in R/R follicular lymphoma: Focus on risk stratification and managing the practicalities of CAR T-cell therapy
Watch haemato-oncology experts discuss updates in R/R follicular lymphoma, with a focus on CAR T-cell therapy.
- Apply prognostic and risk stratification strategies that predict treatment response and outcomes and help guide treatment decisions in FL
- Describe the latest efficacy data for CAR T-cell therapies, their positioning in the treatment sequence for R/R FL, and key considerations for patient selection
- Discuss the practical management of CAR T-cell-related toxicities and the importance of a multidisciplinary approach to care
Connecting Symptoms to Quality of Life: The Importance of Considering Patient Wellbeing when Managing Cutaneous T-Cell Lymphoma (CTCL)
Healthcare professionals are asked to report any adverse events via their national reporting system (see Section 4.8 of SmPC). In the UK reporting forms and information can be found at
or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Kyowa Kirin Ltd on +44 (0)1896 664000, email: firstname.lastname@example.org
ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023
ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]
Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the current treatment paradigm for large B-cell lymphoma, the limitations of current […]
Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An expert interview with Umberto Vitolo
Umberto Vitolo is a Haematology Consultant, Candiolo Cancer Institute, Fondazione del Piemonte per l’Oncologia, IRCCS, Candiolo (Torino), Italy. His research interests are haematological malignancies, primarily lymphoma. He is a member of the Italian Society of Haematology, the Italian Society of Experimental Haematology and the American Society of Haematology. He has authored many papers in peer-reviewed […]
Jennifer Brown, ASH 2022: Zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma, ALPINE (phase III) results
The ALPINE study in patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma has shown that zanubrutinib may offer potential advantages over ibrutinib. In this touchONCOLOGY interview, we speak with Dr Jennifer Brown (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss the mechanism of action of zanubrutinib, its potential advantages over ibrutinib and the […]
William Townsend, EHA 2022: Final analysis of the GALLIUM study of obinutuzumab plus chemotherapy in follicular lymphoma
Dr William Townsend shares the latest data from the final analysis of the phase III GALLIUM study, which used the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab plus chemotherapy to follicular lymphoma. The study compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma. The abstract ‘OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM […]
PART TWO: Mazyar Shadman, EHA 2022: MB-106 for the treatment of relapsed/refractory follicular lymphoma: Results of the phase I/II study
In Part Two of this interview, Dr Mazyar Shadman (Fred Hutchinson Cancer Center, Seattle, Was, USA) presents the results of the follicular lymphoma cohort from his ongoing phase I/II clinical trial investigating MB-106 for B-cell lymphoma/CLL. He discusses the positive efficacy and safety data and the next steps in the clinical development of MB-106. Abstract […]